203 related articles for article (PubMed ID: 36270240)
1. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang SM; Lewis SJ; Rhie SJ
J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
[TBL] [Abstract][Full Text] [Related]
2. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
Sember AM; LoFaso ME; Lewis SJ
J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
[TBL] [Abstract][Full Text] [Related]
3. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
[TBL] [Abstract][Full Text] [Related]
4. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.
Lewis SJ; Mueller BA
BMC Nephrol; 2024 Feb; 25(1):73. PubMed ID: 38413858
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
7. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
[TBL] [Abstract][Full Text] [Related]
8. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
Wang C; Bai Y; Li R; Shen C; Zhang J
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
[TBL] [Abstract][Full Text] [Related]
9. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Landmesser KB; Clark JA; Burgess DS
J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
[TBL] [Abstract][Full Text] [Related]
10. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
[TBL] [Abstract][Full Text] [Related]
11. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Maglio D; Kuti JL; Nicolau DP
Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
[TBL] [Abstract][Full Text] [Related]
13. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
[TBL] [Abstract][Full Text] [Related]
14. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
J Intensive Care; 2018; 6():61. PubMed ID: 30221005
[TBL] [Abstract][Full Text] [Related]
15. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
[TBL] [Abstract][Full Text] [Related]
16. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
Areskog Lejbman I; Torisson G; Resman F; Sjövall F
Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
[TBL] [Abstract][Full Text] [Related]
17. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
18. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
[TBL] [Abstract][Full Text] [Related]
19. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
